Clinical Trial Update: Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase II trial results for a capecitabine, oxaliplatin, and bevacizumab regimen in metastatic/unresectable neuroendocrine tumors were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Pamela L. Kunz | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2013-12-10